Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity

19 Jun 2017

Abstract excerpt

Abstract Cytotoxic T lymphocyte (CTL)–based immunotherapies have had remarkable success at generating objective clinical responses in patients with advanced metastatic melanoma. Although the melanocyte differentiation antigens (MDA) MART-1, PMEL, and tyrosinase were among the first melanoma tumor-associated antigens identified and targeted with immunotherapy, expression within normal melanocytes of the eye and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28630054
DOI: 10.1158/2326-6066.cir-17-0051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune ToxicityPMID 28630054Read ↗

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.Semantic proximity Read ↗

Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.Semantic proximity Read ↗

Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomesSemantic proximity Read ↗

Integrated Proteogenomic Deep Sequencing and Analytics Accurately Identify Non-Canonical Peptides in Tumor ImmunopeptidomesSemantic proximity Read ↗

Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility.Semantic proximity Read ↗

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.Semantic proximity Read ↗

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.Semantic proximity Read ↗

A peptide-signal amplification strategy for the detection and validation of neoepitope presentation on cancer biopsiesSemantic proximity Read ↗

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.Semantic proximity Read ↗

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Semantic proximity Read ↗

Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.